Semaglutide vs. Liraglutide
Summary
Both are FDA-approved GLP-1 receptor agonists. The main practical differences are dosing frequency (weekly vs. daily) and that liraglutide (Saxenda) has an FDA weight-management indication for adolescents 12 and older.
At a glance
| Dimension | Semaglutide | Liraglutide |
|---|---|---|
| Dosing frequency | Weekly (injection) or daily (oral) | Daily injection |
| Adolescent weight indication | Varies by product | Yes, Saxenda for ages 12+ |
| Regulatory status | FDA-approved | FDA-approved |
Semaglutide
- Dosing frequency
- Weekly (injection) or daily (oral)
- Adolescent weight indication
- Varies by product
- Regulatory status
- FDA-approved
Liraglutide
- Dosing frequency
- Daily injection
- Adolescent weight indication
- Yes, Saxenda for ages 12+
- Regulatory status
- FDA-approved
What they have in common
- Both are GLP-1 receptor agonists with similar mechanisms and GI side effects.
- Both carry a boxed warning for thyroid C-cell tumors and MEN 2 contraindications.
Material differences
- Liraglutide requires a daily injection; semaglutide is weekly (or oral for diabetes).
- Newer weekly agents generally produce greater average weight loss than liraglutide.
- Saxenda has an adolescent weight-management indication.
Decision considerations
- Whether daily vs. weekly injection fits your routine.
- Age and indication (e.g., adolescent weight management).
- Coverage and cost of each specific product.
Sources
- 1.WEGOVY (semaglutide) injection — Prescribing Information — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
- 2.SAXENDA (liraglutide) injection — Prescribing Information — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
- 3.FDA approves weight management drug for patients aged 12 and older (Saxenda) — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
Last reviewed (yesterday)